Interleukin-6 and insulin-like growth factor-1 synergistically promote the progression of NSCLC.  Tang H1, Bai Y1, Pan G1, Wang X1, Wei Y2, Yang Z1, Zhao J1. Autoimmunity. 2018 Dec;51(8):399-407. doi: 10.1080/08916934.2018.1550079. Epub 2019 Jan 3.

Circulating miRNA-21 and miRNA-23a expression signature as potential biomarkers for early detection of non-small-cell lung cancer. Hetta HF1,2, Zahran AM3, Shafik EA3, et al. Microrna. 2019 Jan 15. doi: 10.2174/1573399815666190115151500. [Epub ahead of print]

Identification of Key Genes and Pathways in Female Lung Cancer Patients Who Never Smoked by a Bioinformatics Analysis. Shi K1,2, Li N3, Yang M3, Li W1,2. J Cancer. 2019 Jan 1;10(1):51-60. doi: 10.7150/jca.26908. eCollection 2019.

Impact of Slice Thickness on the Predictive Value of Lung Cancer Screening Computed Tomography in the Evaluation of Coronary Artery Calcification. Christensen JL1, Sharma E1, Gorvitovskaia AY1, et al. J Am Heart Assoc. 2019 Jan 8;8(1):e010110. doi: 10.1161/JAHA.118.010110.

Lung cancer screening: Practice guidelines and insurance coverage are not enough. McDonnell KK1, Estrada RD1, Dievendorf AC1, Blew L1, Sercy E2, Khan S2, Hardin JW3, Warden D1, Eberth JM3. J Am Assoc Nurse Pract. 2019 Jan;31(1):33-45. doi: 10.1097/JXX.0000000000000096.

Safety and diagnostic performance of pulmonologists performing electromagnetic guided percutaneous lung biopsy (SPiNperc). Mallow C1, Lee H1, Oberg C2, et al. Respirology. 2019 Jan 24. doi: 10.1111/resp.13471. [Epub ahead of print]

Molecular Testing for EGFR Mutations and ALK Rearrangements in the Cytological Specimens From the Patients With Non-Small Cell Lung Cancer. Wang X1, Chen S, Emerson RE, et al. Appl Immunohistochem Mol Morphol. 2019 Jan 25. doi: 10.1097/PAI.0000000000000701. [Epub ahead of print]

Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer.  Wilner KD1, Usari T2, Polli A2, Kim EE3. Future Oncol. 2019 Jan 17. doi: 10.2217/fon-2018-0869. [Epub ahead of print]

Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Pirker R1. Curr Opin Oncol. 2019 Jan;31(1):24-28. doi: 10.1097/CCO.0000000000000496.

Shared Decision-making and Lung Cancer Screening: Let’s Get the Conversation Started. Tanner NT1, Silvestri GA2. Chest. 2019 Jan;155(1):21-24. doi: 10.1016/j.chest.2018.10.013. Epub 2018 Oct 22.

Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. Taghizadeh N1, Tremblay A1, Cressman S2, et al. BMJ Open. 2019 Jan 17;9(1):e024719. doi: 10.1136/bmjopen-2018-024719.

Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients with Minimal Smoking History. Dagogo-Jack I1, Robinson H2, Mino-Kenudson M3, Farago AF4, Kamesan V4, Iafrate AJ2, Shaw AT4, Lennerz JK2. J Thorac Oncol. 2019 Jan 17. pii: S1556-0864(19)30024-3. doi: 10.1016/j.jtho.2018.12.032. [Epub ahead of print]

Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. Kim DD1, Cohen JT2, Wong JB3, Mohit B4, Fendrick AM5, Kent DM6, Neumann PJ7. Health Aff (Millwood). 2019 Jan;38(1):60-67. doi: 10.1377/hlthaff.2018.05148.

Barriers to Lung Cancer Screening Engagement from the Patient and Provider Perspective. Wang GX1, Baggett TP1, Pandharipande PV1, Park ER1, Percac-Lima S1, Shepard JO1, Fintelmann FJ1, Flores EJ1. Radiology. 2019 Feb;290(2):278-287. doi: 10.1148/radiol.2018180212. Epub 2019 Jan 8.

The Importance of Smoking Cessation on Surgical Outcome in Primary Lung Cancer. Fukui M1, Suzuki K2, Matsunaga T1, Oh S1, Takamochi K1. Ann Thorac Surg. 2019 Jan 2. pii: S0003-4975(18)31871-X. doi: 10.1016/j.athoracsur.2018.12.002. [Epub ahead of print]

The Reach and Feasibility of an Interactive Lung Cancer Screening Decision Aid Delivered by Patient Portal. Dharod A1,2, Bellinger C3, Foley K2, Case LD4, Miller D1,2. Appl Clin Inform. 2019 Jan;10(1):19-27. doi: 10.1055/s-0038-1676807. Epub 2019 Jan 9.

Opinions and Practices of Lung Cancer Screening by Physician Specialty. Henderson LM1, Marsh MW2, Benefield TS3, et al. N C Med J. 2019 Jan-Feb;80(1):19-26. doi: 10.18043/ncm.80.1.19.

A National Analysis of Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Stage I Non-small-cell Lung Cancer. Yang CJ1, Kumar A1, Klapper JA1, Hartwig MG1, Tong BC1, Harpole DH Jr1, Berry MF2, D’Amico TA1. Ann Surg. 2019 Jan;269(1):163-171. doi: 10.1097/SLA.0000000000002342.

Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database. Bailey KL1, Merchant N1, Seo YJ1, Elashoff D2, Benharash P1,3, Yanagawa J4,5. World J Surg. 2019 Jan 2. doi: 10.1007/s00268-018-04900-0. [Epub ahead of print]

Sevoflurane Effect on Cognitive Function and the Expression of Oxidative Stress Response Proteins in Elderly Patients undergoing Radical Surgery for Lung Cancer. Qin Y1, Ni J1, Kang L1, Zhong Z1, Wang L1, Yin S1. J Coll Physicians Surg Pak. 2019 Jan;29(1):12-15. doi: 10.29271/jcpsp.2019.01.12.

Survival and resected lymph nodes number during sublobectomy for N0 Non-Small Cell Lung Cancer ≤ 2cm. Ding H1, Wang H2, Xu L2, Song N2, Jiang G2. Ann Thorac Surg. 2019 Jan 22. pii: S0003-4975(19)30083-9. doi: 10.1016/j.athoracsur.2018.12.024. [Epub ahead of print]

Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Paluri R1, Madan A1, Li P1, Jones B1, Saleh M1, Jerome M1, Miley D1, Keef J1, Robert F2. Cancer Chemother Pharmacol. 2019 Jan 2. doi: 10.1007/s00280-018-3761-y. [Epub ahead of print]

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. Lai WV1, Lebas L2, Barnes TA3, et al. Eur J Cancer. 2019 Jan 24;109:28-35. doi: 10.1016/j.ejca.2018.11.030. [Epub ahead of print]

ALK Inhibitors in the Treatment of ALK Positive NSCLC. Khan M1,2, Lin J1, Liao G1, et al. Front Oncol. 2019 Jan 9;8:557. doi: 10.3389/fonc.2018.00557. eCollection 2018.

Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer. Spencer SA1, Riley AC1, Matthew A1, Di Pasqua AJ1. Ann Pharmacother. 2019 Jan 13:1060028018824578. doi: 10.1177/1060028018824578. [Epub ahead of print]

An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer. Patil PD1, Shapiro M2, Hashemi Sadraei N3, Pennell NA1. Oncologist. 2019 Jan 2. pii: theoncologist.2018-0857. doi: 10.1634/theoncologist.2018-0857. [Epub ahead of print]

Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing. Cook JW1, McGrath MK1, Dixon MD1, Switchenko JM2, Harvey RD1, Pentz RD3. Ther Adv Med Oncol. 2019 Jan 6;11:1758835918818335. doi: 10.1177/1758835918818335. eCollection 2019.

Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cusato J1, Genova C2, Tomasello C3, et al. Cancers (Basel). 2019 Jan 21;11(1). pii: E125. doi: 10.3390/cancers11010125.

Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Rogado J1, Sánchez-Torres JM1, Romero-Laorden N1, et al. Eur J Cancer. 2019 Jan 22;109:21-27. doi: 10.1016/j.ejca.2018.10.014. [Epub ahead of print]

Safety of Electromagnetic Navigation Bronchoscopy in Patients With COPD: Results From the NAVIGATE Study. Towe CW1, Nead MA2, Rickman OB3, Folch EE4, Khandhar SJ5, Perry Y1, Linden PA1. J Bronchology Interv Pulmonol. 2019 Jan;26(1):33-40. doi: 10.1097/LBR.0000000000000522.

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer. Wang Y1,2, Kim TH2,3, Fouladdel S2,4, et al. Sci Rep. 2019 Jan 24;9(1):566. doi: 10.1038/s41598-018-36096-7. Zhang Z1,2, Soni P5, Qin A4, Zhao L6, Azizi E2,4, Lawrence TS5, Ramnath N4, Cuneo KC7,8, Nagrath S9,10,11.

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Foster CC1, Sher DJ2, Rusthoven CG3, Verma V4, Spiotto MT5,6, Weichselbaum RR5, Koshy M5,6. Radiat Oncol. 2019 Jan 28;14(1):18. doi: 10.1186/s13014-019-1222-3.

Predictive factors for response and survival in a cohort of oligometastatic patients treated with Stereotactic Body Radiation Therapy. Franceschini D1, De Rose F2, Franzese C2, et al. Int J Radiat Oncol Biol Phys. 2019 Jan 7. pii: S0360-3016(18)34231-7. doi: 10.1016/j.ijrobp.2018.12.049. [Epub ahead of print]

Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer: An Analysis of 288,670 Patients. Cheng M1, Jolly S2, Quarshie WO3, Kapadia N4, Vigneau FD3, Kong FS5. J Cancer. 2019 Jan 1;10(1):168-177. doi: 10.7150/jca.26600. eCollection 2019.

Definitive Radiation for Stage I lung cancer in a screened population: Results from the I-ELCAP.  Berlin E1, Buckstein M2, Yip R3, Yankelevitz DF3, Rosenzweig K2, Henschke CI4; I-ELCAP  Int J Radiat Oncol Biol Phys. 2019 Jan 21. pii: S0360-3016(19)30110-5. doi: 10.1016/j.ijrobp.2019.01.069. [Epub ahead of print]

Differences in United States insurance payer policies and American Society for Radiation Oncology’s (ASTRO) model policy on stereotactic body radiation therapy (SBRT). Roach MC1, Thomas TO2, Paravati AJ3, Mahajan A4. Int J Radiat Oncol Biol Phys. 2019 Jan 21. pii: S0360-3016(19)30040-9. doi:10.1016/j.ijrobp.2019.01.005. [Epub ahead of print]

Retrospective study of the efficacy and toxicity of lobaplatin-etoposide chemotherapy in small cell lung cancer. Gu L1, Zhong D1, Yu T1, Tang P1, Meng F1, Qin Q1. Thorac Cancer. 2019 Jan 2. doi: 10.1111/1759-7714.12936. [Epub ahead of print]

Stereotactic radiosurgery for brain metastases from newly diagnosed small cell lung cancer: practice patterns and outcomes. Jiang W1,2, Haque W1, Verma V3, Butler B1, Teh BS1. Acta Oncol. 2019 Jan 24:1-8. doi: 10.1080/0284186X.2018.1562207. [Epub ahead of print]

Surgical outcomes of early-stage small-cell lung cancer: single-center experience. Sayan M1, Satir Turk M1, Celik A1, Cuneyt Kurul I1, Irfan Tastepe A1. Asian Cardiovasc Thorac Ann. 2019 Jan 19:218492319826724. doi: 10.1177/0218492319826724. [Epub ahead of print]

A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial. Pujol JL1, Greillier L2, Audigier-Valette C3, et al. J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30025-5. doi: 10.1016/j.jtho.2019.01.008. [Epub ahead of print]

The role of immunotherapy in small cell lung cancer. Calles A1,2, Aguado G3, Sandoval C3, Álvarez R3,4. Clin Transl Oncol. 2019 Jan 12. doi: 10.1007/s12094-018-02011-9. [Epub ahead of print]

Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.  Pacheco J1, Bunn PA2. Clin Lung Cancer. 2019 Jan 2. pii: S1525-7304(18)30356-5. doi: 10.1016/j.cllc.2018.12.019. [Epub ahead of print]

Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small-Cell Lung Cancer. Reck M1, Horn L2, Novello S3, et al. J Thorac Oncol. 2019 Jan 21. pii: S1556-0864(19)30029-2. doi: 10.1016/j.jtho.2019.01.010. [Epub ahead of print]

Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and their Family Caregivers: Results of a Pilot Randomized Controlled Trial. Milbury K1, Liao Z1, Shannon V1, et al. Psychooncology. 2019 Jan 18. doi: 10.1002/pon.4991. [Epub ahead of print]

Communication along Milestones in Lung Cancer Patients with Advanced Disease. Villalobos M, Siegle A, Hagelskamp L, Jung C, Thomas M. Oncol Res Treat. 2019 Jan 25;42(1-2). doi: 10.1159/000496407. [Epub ahead of print]

The Effect of 20-Minute Mindful Breathing on the Rapid Reduction of Dyspnoea at Rest in Patients with Lung Diseases: A Randomized Controlled Trial. Tan SB1, Liam CK1, Pang YK1, et al. J Pain Symptom Manage. 2019 Jan 23. pii: S0885-3924(19)30042-9. doi:

Interprofessional Perspectives on Providing Spiritual Care for Patients With Lung Cancer in Outpatient Settings. Siler S1, Mamier I1, Winslow BW1, Ferrell BR2. Oncol Nurs Forum. 2019 Jan 13;46(1):49-58. doi: 10.1188/19.ONF.49-58.

Pilot Study of Self-care Breath Training Exercise for Reduction of Chronic Dyspnea. Deng G1, Feinstein MB, Benusis L, Tin AL, Stover DE. J Cardiopulm Rehabil Prev. 2019 Jan;39(1):56-59. doi: 10.1097/HCR.0000000000000368.

The Influence of Patient Race and Activation on Pain Management in Advanced Lung Cancer: a Randomized Field Experiment. Shields CG1,2,3, Griggs JJ4,5, Fiscella K6,7,8, et al. J Gen Intern Med. 2019 Jan 10. doi: 10.1007/s11606-018-4785-z. [Epub ahead of print]

Traditional Chinese medicine Ze-Qi-Tang formula inhibit growth of non-small-cell lung cancer cells through the p53 pathway. Xu Z1, Zhang F2, Zhu Y1, et al. J Ethnopharmacol. 2019 Jan 17. pii: S0378-8741(18)34126-6. doi: 10.1016/j.jep.2019.01.007. [Epub ahead of print]

Evaluation of percentage-based radon testing requirements for federally-funded multi-family housing projects. Neri A1. J Occup Environ Hyg. 2019 Jan 8:1-8. doi: 10.1080/15459624.2019.1566735. [Epub ahead of print]

Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved Community. Su CT1,2, Chau V1, Halmos B3, et al. Am J Clin Oncol. 2019 Jan 16. doi: 10.1097/COC.0000000000000516. [Epub ahead of print]

The Changing Face of Lung Cancer: Survivor Perspectives on Patient Engagement. Fitch MI1. Asia Pac J Oncol Nurs. 2019 Jan-Mar;6(1):17-23. doi: 10.4103/apjon.apjon_43_18.

Brain metastases. Achrol AS1, Rennert RC2, Anders C3, et al. Nat Rev Dis Primers. 2019 Jan 17;5(1):5. doi: 10.1038/s41572-018-0055-y.

The QuitIT Coping Skills Game for Promoting Tobacco Cessation Among Smokers Diagnosed With Cancer: Pilot Randomized Controlled Trial. Krebs P1, Burkhalter J2, Fiske J3, et al. JMIR Mhealth Uhealth. 2019 Jan 10;7(1):e10071. doi: 10.2196/10071.

A global perspective on coal-fired power plants and burden of lung cancer. Lin CK1, Lin RT2, Chen T3, Zigler C3, Wei Y4, Christiani DC4,5. Environ Health. 2019 Jan 28;18(1):9. doi: 10.1186/s12940-019-0448-8.

“A Tool, Not a Crutch”: Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering. Hamilton JG1, Genoff Garzon M1, et al. J Oncol Pract. 2019 Jan 28:JOP1800417. doi: 10.1200/JOP.18.00417. [Epub ahead of print]

Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment. Herrero Rivera D1, Nieto-Guerrero Gómez JM2, Cacicedo Fernández de Bobadilla J3, et al. Clin Transl Oncol. 2019 Jan 24. doi: 10.1007/s12094-019-02047-5. [Epub ahead of print]